Press Release: New clinical study validates dsm-firmenich’s CBtru® as a promising pathway for patient-friendly CBD-based therapies

dsm-firmenich, a leading innovator in health, nutrition, and beauty reveals new clinical data confirming that the bioavailability of cannabidiol (CBD)-based therapies can be enhanced in oral solid dosage forms.

dsm-firmenich, a leading innovator in health, nutrition, and beauty, today reveals new clinical data confirming that the bioavailability of cannabidiol (CBD)-based therapies can be enhanced in oral solid dosage forms. The clinical trial results demonstrated that dsm-firmenich’s CBD drug product intermediate, CBtru®, is absorbed into the bloodstream at a similar level compared to Epidiolex®, the first (and to this date only) commercially approved CBD drug product on the market, which is in a liquid oil-based dosage form. This is the first time that a solid CBD formulation has shown comparable absorption results to the liquid oil-based reference product. With this evidence, CBtru® presents a new opportunity for pharmaceutical companies to develop solid oral CBD-based therapies, offering patients a more convenient and user-friendly alternative to current oil-based medicines.